Latest stories on VKTX
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
Yahoo Finance63 · neutralanalyst
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
The Motley Fool63 · neutralanalyst
Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout
Investing.com Markets58 · neutralgeneral
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
The Motley Fool42 · neutralanalyst
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
The Motley Fool54 · neutralanalyst
Viking Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire56 · neutralgeneral
VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3
Stocktwits News56 · neutralproduct/pr
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
The Motley Fool34 · bearishgeneral
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
The Motley Fool48 · neutralgeneral
Viking Therapeutics Price Target Lowered To 65 From 75 At Jpmorgan
The Fly38 · neutralanalyst
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
TipRanks57 · neutralanalyst
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Yahoo Top57 · neutralanalyst
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
The Motley Fool57 · neutralgeneral
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)
Seeking Alpha56 · neutralearnings
Viking Therapeutics Participates In A Conference Call With Cantor
The Fly55 · neutralgeneral
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
The Motley Fool48 · neutralgeneral
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
The Motley Fool67 · bullishm&a
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
Stocktwits News67 · bullishgeneral
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Stocktwits News54 · neutralproduct/pr
Viking expects oral VK2735 Phase III start in fourth quarter as VANQUISH targets 78-week dosing
Seeking Alpha63 · neutralproduct/pr
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress
Stocktwits News58 · neutralproduct/pr